Hercules Capital Provides $50MM in Debt Financing to AmplifyBio
AmplifyBio augmented its balance sheet with non-dilutive debt financing, whereby it may borrow a principal amount of up to $50 million from Hercules Capital.
AmplifyBio augmented its balance sheet with non-dilutive debt financing, whereby it may borrow a principal amount of up to $50 million from Hercules Capital.
Silicon Valley Bank and Hercules Capital provided a $300 million credit facility to Oak Street Health, a network of value-based primary care centers for adults on Medicare. The financing is intended to provide Oak Street Health with operational and strategic capital for the next several years.
Tricida entered into a debt facility with Hercules Capital. The total amount of the debt facility is $125 million of which $100 million will be available for drawdown at Tricida’s option subject to the achievement of certain milestones.
Replimune Group, a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, obtained a $200 million non-dilutive term loan facility from Hercules Capital.
Automation Anywhere, a global robotic process automation company, secured $200 million in financing from Silicon Valley Bank, SVB Capital and Hercules Capital. The financing is intended to provide operational and strategic capital for the next several years.
Provention Bio, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, secured a term loan facility of up to $125 million with Hercules Capital.
Alladapt Immunotherapeutics, a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, entered into a term loan agreement for up to $50 million with Hercules Capital.
atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, entered into a term loan facility for up to $175 million with Hercules Capital.
Gritstone bio, a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, entered into an $80 million credit facility with Hercules Capital and Silicon Valley Bank.
Hercules Capital increased its existing credit facilities with MUFG Bank and Sumitomo Mitsui Banking Corporation from a combined $500 million to $720 million, subject to a borrowing base, leverage and other restrictions.